Charles Schwab’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $18.1M | Sell |
|
|||||
|
2025
Q2 | $22.4M | Buy |
|
|||||
|
2025
Q1 | $21.5M | Sell |
|
|||||
|
2024
Q4 | $25.8M | Buy |
|
|||||
|
2024
Q3 | $33M | Buy |
|
|||||
|
2024
Q2 | $22.1M | Buy |
|
|||||
|
2024
Q1 | $22.6M | Buy |
|
|||||
|
2023
Q4 | $22.6M | Buy |
|
|||||
|
2023
Q3 | $14.1M | Buy |
|
|||||
|
2023
Q2 | $17.4M | Buy |
|
|||||
|
2023
Q1 | $14.9M | Sell |
|
|||||
|
2022
Q4 | $17.2M | Buy |
|
|||||
|
2022
Q3 | $15.1M | Sell |
|
|||||
|
2022
Q2 | $32.9M | Buy |
|
|||||
|
2022
Q1 | $39.3M | Buy |
|
|||||
|
2021
Q4 | $44.2M | Buy |
|
|||||
|
2021
Q3 | $46.3M | Buy |
|
|||||
|
2021
Q2 | $47.4M | Sell |
|
|||||
|
2021
Q1 | $68.3M | Buy |
|
|||||
|
2020
Q4 | $75.2M | Buy |
|
|||||
|
2020
Q3 | $40.5M | Buy |
|
|||||
|
2020
Q2 | $29.3M | Buy |
|
|||||
|
2020
Q1 | $15.2M | Buy |
|
|||||
|
2019
Q4 | $14.3M | Buy |
|
|||||
|
2019
Q3 | $14.1M | Buy |
|
|||||
|
2019
Q2 | $20.2M | Buy |
|
|||||
|
2019
Q1 | $20.9M | Buy |
|
|||||
|
2018
Q4 | $11.4M | Buy |
|
|||||
|
2018
Q3 | $19.7M | Buy |
|
|||||
|
2018
Q2 | $18.8M | Buy |
|
|||||
|
2018
Q1 | $11.4M | Buy |
|
|||||
|
2017
Q4 | $8M | Sell |
|
|||||
|
2017
Q3 | $9.67M | Sell |
|
|||||
|
2017
Q2 | $13.6M | Buy |
|
|||||
|
2017
Q1 | $14.4M | Buy |
|
|||||
|
2016
Q4 | $14M | Buy |
|
|||||
|
2016
Q3 | $13.1M | Buy |
|
|||||
|
2016
Q2 | $8.36M | Buy |
|
|||||
|
2016
Q1 | $10.7M | Buy |
|
|||||
|
2015
Q4 | $17.3M | Buy |
|
|||||
|
2015
Q3 | $13.7M | Buy |
|
|||||
|
2015
Q2 | $9.49M | Buy |
|
|||||
|
2015
Q1 | $3.29M | Buy |
|
|||||
|
2014
Q4 | $1.83M | Buy |
|
|||||
|
2014
Q3 | $2.22M | Buy |
|
|||||
|
2014
Q2 | $666K | Buy |
|
|||||
|
2014
Q1 | $246K | Buy |
|